Seborrheic Dermatitis Market Report 2024 - Market Size, Growth Rate, Major Drivers And Key Trends | Pfizer Inc., Johnson and Johnson, Merck and Co. Inc., AbbVie Inc., Bayer AG

"The seborrheic dermatitis market size has grown rapidly in recent years. It will grow from $2.46 billion in 2023 to $2.76 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to improved diagnosis and awareness, growing aging population, lifestyle factors, dermatological advancements, consumer preferences for cosmetic solutions..

The seborrheic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $4.14 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to focus on natural and herbal products, regulatory support for new therapies, global health preparedness, patient advocacy and support.. Major trends in the forecast period include integration of dermatological technologies, research on the role of microbiome, customized treatment plans, telemedicine and e-health solutions, technological innovations in skincare..

Market Overview -
Seborrheic dermatitis is a chronic skin condition that typically impacts areas with abundant oil glands, such as the scalp, leading to redness, itching, flaking, and greasy or yellowish scales resembling dandruff. The treatment for the disease includes various medical strategies and interventions, such as medicated shampoos and prescription medications, employed to manage the symptoms and complications associated with seborrheic dermatitis.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=13159&type=smp

Rising Prevalence Of Dermatological Diseases Fuels Seborrheic Dermatitis Market Growth
The increasing prevalence of dermatological diseases is expected to propel the growth of the seborrheic dermatitis market going forward. Dermatological diseases refer to various medical conditions affecting the skin, hair, nails, and mucous membranes. The treatment of dermatological diseases provides relief from discomfort, improves the appearance of the skin, and, in many cases, helps prevent complications such as infections or scarring, thereby enhancing the overall quality of life for affected individuals. For instance, in December 2022, according to the data from the National Psoriasis Foundation, a US-based non-profit organization, about 125 million people worldwide were affected by psoriasis (a type of dermatological disease), which is roughly 2-3% of the global population. Additionally, over 8 million Americans were reported to have psoriasis in 2022. Therefore, the increasing prevalence of dermatological diseases will drive the growth of the seborrheic dermatitis market.

Competitive Landscape -
Major companies operating in the seborrheic dermatitis market report are Pfizer Inc., Johnson and Johnson, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Co, Abbott Laboratories, GlaxoSmithKline Plc, Acella Pharmaceuticals LLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Galderma S.A., Dr. Reddy's Laboratories Ltd., Cipla Limited, Getinge AB, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited, Monarch Pharmachem, Alliance Pharma plc, Genentech Inc., Zydus Group, Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Introduces Innovative Roflumilast Foam For Seborrheic Dermatitis
Major companies operating in the seborrheic dermatitis market are focusing on developing novel and more effective medical therapies, such as roflumilast foam, to drive revenues in the market. Roflumilast foam is an innovative and improved daily-use topical treatment for inflammatory skin conditions, focusing on hair-bearing areas like the scalp, face, and trunk. For instance, in April 2023, Arcutis Biotherapeutics Inc., a US-based medical dermatology company, unveiled its new drug, roflumilast foam 0.3%, the first topical drug with a unique mechanism of action for seborrheic dermatitis in over two decades to be approved by the Food and Drug Administration (FDA), a US-based government agency. Roflumilast foam is an investigational, once-daily, topical formulation of a highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor developed to treat inflammatory dermatoses, particularly in hair-bearing areas of the body. This drug is used to treat seborrheic dermatitis in individuals aged nine years and older.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/seborrheic-dermatitis-global-market-report

Key Segments -
The seborrheic dermatitis market covered in this report is segmented -
1) By Treatment: Anti-Inflammatory, Antifungal, Corticosteroid Lotions, Sulfur Products, Other Treatments
2) By Diagnosis: Physical Examination, Biopsy, Other Diagnoses
3) By Dosage Form: Creams, Shampoos, Ointments, Gels, Other Dosage Forms
4) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.